Skip to content

MacuLogix Announces Collaboration with ALLDocs

The Company Aims to Demonstrate Clinical and Financial Impact of Early AMD Detection Utilizing the AdaptDx

 

MIDDLETOWN, PA, August 22, 2016 – MacuLogix,® Inc., a pioneer in the early detection and tracking of retinal diseases, today announced it is collaborating with several ALLDocs (The Association of LensCrafters Leaseholding Doctors) members to demonstrate the clinical and financial impact of the AdaptDx within a LensCrafters’ practice setting. MacuLogix’ AdaptDx® dark adaptometer enables early detection and monitoring of age-related macular degeneration (AMD). 

In addition, MacuLogix will support the ALLDocs Annual Meeting in Key Largo, FL, October 23-28, 2016 as a Silver Sponsor, where the company will share results of the collaboration and demonstrate the AdaptDx.

“MacuLogix is excited to work with ALLDocs because of the strong medical focus of its member optometrists. Adding the AdaptDx to their diagnostic toolkit will allow ALLDocs practices to detect subclinical AMD at least three years before it’s clinically evident,” said John G. Edwards, CEO of MacuLogix. “By proactively testing their patients who are over age 50 and have risk factors for AMD, these practices will be at an advantage for preserving vision through early detection and monitoring of the disease.”

The AdaptDx is the first instrument cleared by the U.S. Food and Drug Administration (FDA) to provide a practical and objective measurement of dark adaptation function, which is severely impaired in age-related macular degeneration (AMD), retinitis pigmentosa (RP), and other macular degenerations. The AdaptDx has been clinically validated in numerous clinical studies involving over 1,000 patients, conducted at research centers such as Harvard University, the National Eye Institute, and the University of Alabama at Birmingham. 

Demonstrating the Clinical and Financial Impact of Early Detection

MacuLogix is working with three ALLDocs members to demonstrate how the use of AdaptDx can impact patient care and satisfaction. Participants include Dennis Brtva, OD, in Peoria, IL, who has owned an AdaptDx since early 2015; Lisa Greene, OD, in Asheville, NC; and Dale Stein, OD, in Voorhees, NJ. Results from their real-world experience will be shared during the ALLDocs Annual Meeting.

“Our goal is to provide access to state-of-the-art technology, such as the AdaptDx dark adaptometer, that can help our members improve patient care and aid in helping prevent the leading cause of blindness in people 55 and older,” said Kerry Gelb, OD, President of ALLDocs. “Because ALLDocs members like to stay ahead of the curve when it comes to technology, we know they will be interested in learning about the potential of the AdaptDx as an aid in the early diagnosis of AMD.”

 

About ALLDocs

ALLDocs, also known as The Association of LensCrafters Leaseholding Doctors, is the second largest independent optometry group in the U.S.  Founded in 1986, ALLDocs is a vibrant, organized, independent group whose mission is to improve and brand its individual optometric practices, as well as work closely with its valued LensCrafters partners.

 

About MacuLogix

MacuLogix, Inc. is a pioneer in the early detection and tracking of retinal diseases. The Company’s AdaptDx is the first practical measurement tool for dark adaptation. Dark adaptation is known to be substantially impaired in degenerative diseases of the macula such as age-related macular degeneration (AMD) and inherited macular dystrophies. Based on significant technical advances, the AdaptDx provides doctors with an easy-to-use functional test for macular degeneration similar to routine perimetry testing for glaucoma.